STOCK TITAN

Q/C Technologies extends Series H maturity to Sept. 2, 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Q/C Technologies, Inc. entered an omnibus amendment agreement with PharmaCyte Biotech, Inc., which holds at least a majority of the outstanding Series G and Series H preferred stock. The Series G and Series H certificates were amended to revise amendment provisions and PharmaCyte’s beneficial ownership limitations; Q/C Technologies filed both amendments on November 20, 2026, and they became effective upon filing.

The Series H preferred stock maturity date was extended from March 2, 2027, to September 2, 2027 through an amendment filed November 20, 2026. Under the agreement, PharmaCyte also agreed to amend the amendment and beneficial ownership limitation provisions in the Series G long-term warrants it holds.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Series H preferred stock maturity date September 2, 2027 Extended from March 2, 2027
beneficial ownership limitations financial
"amends the beneficial ownership limitations with respect to PharmaCyte"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
Certificate of Designations regulatory
"terms are set forth in the Certificate of Designations"
A certificate of designations is a formal legal document that spells out the specific rights and rules attached to a particular class of stock, most often preferred shares. It tells investors who gets paid first, what dividends or conversion rights exist, and any voting or liquidation priorities—like an instruction sheet that decides which shareholders get preference if a company pays out or is sold. Those terms directly affect a security’s value and risk.
Required Holders technical
"thereby constitutes the Required Holders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does QCLS’s Series H preferred stock mature?

The Series H preferred stock maturity date is September 2, 2027, extended from March 2, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001321834 0001321834 2026-11-20 2026-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 20, 2026

 

Q/C Technologies, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-36268   22-2983783

(State or other jurisdiction

of incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

 

333 Bush Street, Suite 1400    
San Francisco, CA   94104
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (856) 848-8698

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 per share   QCLS   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

Omnibus Amendment Agreement

 

As previously disclosed, on May 20, 2024, Q/C Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Series G Purchase Agreement”) with certain accredited investors (the “Holders”) pursuant to which the Company issued and sold to the Holders in a private placement (i) shares of the Company’s Series G convertible preferred stock, par value $0.001 per share (the “Series G Preferred Stock”), (ii) certain warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), with a term of five (5) years from the date of issuance (the “Series G Long-Term Warrants”), and (iii) warrants to purchase shares of the Company’s Common Stock, with an initial term of eighteen (18) months from the date of issuance. The terms of the Series G Preferred Stock are set forth in the Certificate of Designations of Series G Preferred Stock filed with the Secretary of State of the State of Delaware (the “Secretary of State”) on May 21, 2024 (as amended, the “Series G Certificate of Designations”).

 

As previously disclosed, on September 2, 2025, the Company entered into a Securities Purchase Agreement (the “Series H Purchase Agreement”) with the Holders pursuant to which the Company issued and sold to the Holders (i) shares of the Company’s Series H Convertible Preferred Stock, par value $0.001 per share (the “Series H Preferred Stock”), and (ii) accompanying warrants to purchase shares of Common Stock (the “Series H Warrants”). The terms of the Series H Preferred Stock are set forth in the Certificate of Designations of Series H Convertible Preferred Stock filed with the Secretary of State on September 3, 2025 (as amended, the “Series H Certificate of Designations”).

 

On November 20, 2026, the Company entered into an Omnibus Amendment Agreement (the “Omnibus Agreement”) with PharmaCyte Biotech, Inc. (“PharmaCyte”), which holds at least a majority of the outstanding shares of each of the Series G Preferred Stock and the Series H Preferred Stock and thereby constitutes the Required Holders (as defined under each of the Series G Certificate of Designations and the Series H Certificate of Designations). Pursuant to the Omnibus Agreement, PharmaCyte agreed to amend (i) the Series G Certificate of Designations by filing a Certificate of Amendment (the “Series G Amendment”) with the Secretary of State, (ii) the Series H Certificate of Designations by filing a Certificate of Amendment (the “Series H Amendment”) with the Secretary of State, and (iii) the Series G Long-Term Warrants held by PharmaCyte to amend the amendment provisions and the beneficial ownership limitation provisions contained therein.

 

Each of the Series G Amendment and the Series H Amendment amends the amendment provisions as set forth therein and amends the beneficial ownership limitations with respect to PharmaCyte. On November 20, 2026, the Company filed the Series G Amendment and the Series H Amendment with the Secretary of State, thereby amending the Series G Certificate of Designations and the Series H Certificate of Designations, respectively. Each of the Series G Amendment and the Series H Amendment became effective with the Secretary of State upon filing.

 

The foregoing descriptions of the Omnibus Agreement, the Series G Amendment, and the Series H Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of each such document, copies of which are filed as Exhibit 10.1, Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

 

Item 3.03 Material Modification to Rights of Security Holders

 

The matters described in Item 1.01 of this Current Report on Form 8-K related to the Omnibus Agreement, the Series G Amendment and the Series H Amendment are incorporated herein by reference.

 

As previously disclosed in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 16, 2026, the Company entered into a Consent and Warrant Exchange Agreement on November 15, 2026 (the “Consent Agreement”) with PharmaCyte. Under the Consent Agreement, PharmaCyte consented to an amendment to the Series H Certificate of Designations that extends the maturity date of the Series H Preferred Stock from March 2, 2027 to September 2, 2027 (the “Series H Maturity Amendment”). On November 20, 2026, the Company filed the Series H Maturity Amendment with the Secretary of State.

 

The foregoing description of the Series H Maturity Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Series H Maturity Amendment, a copy of which is filed as Exhibit 3.3 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number   Description
3.1   Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock (beneficial ownership limitation).
3.2   Certificate of Amendment of Certificate of Designations of Series H Convertible Preferred Stock (beneficial ownership limitation).
3.3   Certificate of Amendment of Certificate of Designations of Series H Convertible Preferred Stock (maturity date amendment).
10.1   Omnibus Amendment Agreement, dated as of November 20, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Q/C TECHNOLOGIES, INC.
     
Date: November 20, 2026 By: /s/ Joshua Silverman
  Name: Joshua Silverman
  Title: Executive Chairman

 

 

 

Filing Exhibits & Attachments

7 documents

Keep reading